EFIKASI DAN KEAMANAN INHIBITOR PCSK9 DALAM PENCEGAHAN STROKE ISKEMIK: LITERATURE REVIEW

Authors

  • Lathifa Shofia Ummu Universitas Airlangga, Surabaya, Indonesia
  • Suharjono Universitas Airlangga, Surabaya, Indonesia

DOI:

https://doi.org/10.36423/pharmacoscript.v8i1.2047

Keywords:

Inhibitor PCSK9, Stroke Iskemik, LDL-C

Abstract

Stroke iskemik merupakan kelainan neurologis yang ditandai dengan berkurangnya suplai darah ke otak sehingga mengalami kekurangan oksigen dan nutrisi kemudian menjadi nekrotik. salah satu penyebab stroke iskemik yang paling umum adalah terbentuknya aterosklerosis yang dikaitkan dengan kejadian stroke berulang. Penggunaan inhibitor PCSK9 dapat diberikan sebagai terapi pencegahan stroke iskemik dan kejadian stroke berulang sehingga perlu dilakukan kajian tentang efikasi dan keamanan inhibitor PCSK9 dalam pencegahan stroke dan penurunan angka kejadian stroke berulang. Penelitian ini menggunakan metode literature review dengan pencarian artikel dibatasi pada rentang waktu antara 2013 – 2023. Inhibitor PCSK9 secara signifikan dapat menurunkan LDL-C dan trigliserida sehingga mengurangi pembentukan aterosklerosis yang merupakan penyebab utama kejadian stroke. Kesimpulannya, inhibitor PCSK9 dapat digunakan sebagai pencegahan stroke iskemik dan stroke berulang tetapi pada beberapa penelitian belum menunjukkan keamanan ditandai dengan adanya efek samping kejang dan reaksi terhadap tempat suntikan sehingga perlu dilakukan penelitian lebih lanjut.

References

Aung, H. H., Lame, M. W., Gohil, K., An, C. Il, Wilson, D. W., & Rutledge, J. C. (2013). Induction of ATF3 gene network by triglyceride-rich lipoprotein lipolysis products increases vascular apoptosis and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(9), 2088–2096. https://doi.org/10.1161/ATVBAHA.113.301375

Castilla-Guerra, L., Fernández-Moreno, M. C., & Rico-Corral, M. A. (2019). Cholesterol and stroke: role of PCSK9 inhibitors. Neurología (English Edition), 34(3), 198–203. https://doi.org/10.1016/j.nrleng.2017.03.005

Cefalù, A. B., Garbelotto, R., Mombelli, G., Pirro, M., Rubba, P., Arca, M., Borghi, C., Bonomo, K., Gonnelli, S., Massaroni, K., Tirone, G., Averna, M., Angelico, F., Cipollone, F., Corghi, E., Faggiano, P., Greco, C., Guasti, L., Lucchi, T., … Zambon, A. (2022). A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 32(11), 2638–2646. https://doi.org/10.1016/j.numecd.2022.07.020

Chakraborty, A., Pang, J., Chan, D. C., Barnett, W., Woodward, A. M., Vorster, M., & Watts, G. F. (2021). Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic. Clinical Cardiology, 44(6), 805–813. https://doi.org/10.1002/clc.23607

Civeira, F., Arca, M., Cenarro, A., & Hegele, R. A. (2022). A mechanism-based operational definition and classification of hypercholesterolemia. Journal of Clinical Lipidology, 16(6), 813–821. https://doi.org/10.1016/j.jacl.2022.09.006

Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022). A Comprehensive Review of PCSK9 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 27, 1–14. https://doi.org/10.1177/10742484221100107

Gencer, B., & Giugliano, R. P. (2020). Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Clinical Cardiology, 43(7), 684–690. https://doi.org/10.1002/clc.23410

Gil-Núñez, A., Masjuan, J., Montaner, J., Castellanos, M., Segura, T., Cardona, P., Tembl, J. I., Purroy, F., Arenillas, J., & Palacio, E. (2022). Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. Neurología (English Edition), 37(2), 136–150. https://doi.org/10.1016/j.nrleng.2020.11.014

Giugliano, R. P., Pedersen, T. R., Saver, J. L., Sever, P. S., Keech, A. C., Bohula, E. A., Murphy, S. A., Wasserman, S. M., Honarpour, N., Wang, H., Pineda, A. L., & Sabatine, M. S. (2020). Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke, 51(5), 1546–1554. https://doi.org/10.1161/STROKEAHA.119.027759

Downloads

Published

2025-02-24

Issue

Vol. 8 No. 1 (2025): Pharmacoscript

Section

Articles

License

Copyright (c) 2025 Lathifa Shofia Ummu, Suharjono

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication, with the work [SPECIFY PERIOD OF TIME] after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).